An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes

Lisa Pleyer¹, Mikkael A Sekeres²

Affiliations

¹ Austrian Group for Medical Tumor Therapy Study Group, Vienna, Austria; Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria. Electronic address: dr.lisa.pleyer@gmail.com.
² Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.

PMID: 36063831
DOI: 10.1016/S2352-3026(22)00252-6

Comment

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes

Lisa Pleyer et al. Lancet Haematol. 2022 Oct.

. 2022 Oct;9(10):e714-e716.

doi: 10.1016/S2352-3026(22)00252-6. Epub 2022 Sep 2.

Authors

Lisa Pleyer¹, Mikkael A Sekeres²

Affiliations

¹ Austrian Group for Medical Tumor Therapy Study Group, Vienna, Austria; Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria. Electronic address: dr.lisa.pleyer@gmail.com.
² Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.

PMID: 36063831
DOI: 10.1016/S2352-3026(22)00252-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

LP has received honoraria for advisory boards or presentations from AbbVie, BMS, and Novartis; and travel or education grants from Novartis, Kite-Gilead, BMS, and BeiGene. MAS has received honoraria for advisory boards from BMS, Kurome, and Novartis.

Comment on

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Lancet Haematol. 2022 Oct;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. Epub 2022 Sep 2. Lancet Haematol. 2022. PMID: 36063832 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes

Affiliations

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources